The global immunoglobulin (IgG) replacement therapy market was anticipated to reach a valuation of US$ 11.8 Billion in the year 2022. With a steady CAGR of 7.4% from 2023 to 2033, this market is expected to reach US$ 12.67 Billion by 2023 and US$ 25.88 Billion by 2033.
Some of the prominent drivers of this market are:
Due to the rising prevalence of CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) among patients as well as patients with bleeding disorders, the global market for IgG replacement treatment is growing quickly. The market for IgG replacement treatment is also expanding as a result of increased investment in the healthcare sector. Also, the market for IgG replacement therapy products is expanding due to the rising number of individuals with autoimmune diseases and other pathological disorders.
There are presently more than 50 distinct Primary Immune Deficiencies (PIDs), including X-lined hypogammaglobulinemia as well as specific antibody deficiency. PIDs are a group of 176 uncommon inherited illnesses. PID affects around 6 million people globally, according to the National Institutes of Health and the USA National Library of Medicine. Throughout the projected period, rising rates of these disorders are anticipated to increase the demand for immunoglobulin replacement therapy.
As it is the best and only accessible form of treatment for acquired as well as primary immunodeficiency illnesses, immunoglobulin replacement therapy is becoming more and more popular. Moreover, sedentary lifestyle practices such as consuming saturated fats, salt, and sweets, engaging in little physical activity, and abusing alcohol heavily have increased the prevalence of these disorders. It's anticipated that the rise would be fueled by the increasing prevalence of lifestyle-related diseases including obesity and problems with the immune system.
Due to the increasing prevalence of Kawasaki illness in children and the growing need for immunoglobulin replacement therapy for its treatment, the Kawasaki disease market is predicted to develop profitably. As steroids, which have significant adverse effects, are the only therapeutic option except for immunoglobulin replacement therapy, their use in treating Kawasaki illness is anticipated to increase over the next several years. Moreover, factors like increased patient awareness levels and an increase in the prevalence of disorders with an inadequate supply of antibodies are anticipated to increase demand for immunoglobulin replacement treatment, hence driving the market.
A large portion of this industry's growth may be attributed to the rising number of FDA approvals. As a result, several national and international businesses are making investments in the IgG replacement therapy industry. For example, Pfizer received approval from the USA FDA in February 2021 for its supplementary biologics license application (sBLA) for PANZYGA, an intravenous immunoglobulin used to treat adult individuals with CIDP or chronic inflammatory demyelinating polyneuropathy.
Also, it has been discovered that the major manufacturers provide technologically cutting-edge methods and platforms for a deeper comprehension of disease biology as well as the introduction of innovative therapies. The European Union increased the cutaquig by Octapharma indication in January 2022. It is a recombinant immunoglobulin that is administered subcutaneously. Patients who require immunoglobulin replacement therapy and have any kind of secondary immunodeficiency are covered by the enlarged indication. Also, with XEMBIFY, Grifols got permission from the health authorities of numerous European Union member states as well as the United Kingdom in March 2022. A cutting-edge 20% subcutaneous immunoglobulin (SCIG) is now authorized for the treatment of primary and certain secondary immunodeficiencies. Such developments are expected to bring in more opportunities in this market from 2023 to 2033.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 12.67 Billion |
| Expected Market value in 2033 | US$ 25.88 Billion |
| Growth Rate (2023 to 2033) | 7.4% |
Immunoglobulin is a type of antibody present in blood plasma. Immunoglobulin (IgG) replacement therapy is a treatment given to boost your antibody level when they are low. Immunoglobulin (IgG) replacement therapy involves infusion of antibody into the body via intravenous or subcutaneous route that strengthens the immune system to fight against several infections.
Immunoglobulin (IgG) replacement therapy is used in the treatment of immunodeficiency disease.Demand for Immunoglobulin (IgG) replacement therapy is increasing as it is the only effective and available therapy option in the market. Immunoglobulin (IgG) replacement therapy market is expected to grow rapidly during the forecast period.
During this COVID-19 pandemic, pharmaceutical companies, medical devices companies and also biotechnology companies are facing rapid challenges that are arising from the disruption in supply chains and the need to change business processes.
Flow of patients into the hospitals and clinics have been reduced as a result number of immunoglobulin (IgG) replacement therapy performed is reduced. There is a lack of supply of various products and equipment required for therapy which is hampering the Immunoglobulin (IgG) replacement therapy market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing prevalence of immunodeficiency diseases is a major factor driving the immunoglobulin (IgG) replacement therapy market. It has been reported that approximately 6 million people are suffering from primary immunodeficiency diseases.
Ageing weakens the immune that leads to higher susceptibility of patients towards acquiring an infectious disease. Hence, increasing geriatric population is expected to boost the Immunoglobulin (IgG) replacement therapy market.
The rising prevalence of lifestyle-associated problems such as antibody deficiency disorder and obesity is also expected to drive growth. Other factors contributing to the growth of the Immunoglobulin (IgG) replacement therapy market are growing healthcare expenditure in many regions and emerging economies.
Based on the route of administration, the intravenous route is most commonly used in the Immunoglobulin (IgG) replacement therapy market. The subcutaneous route of administration is expanding due to fewer side effects and shorter response time.
Based on the application, hypogammaglobulin is dominating the segment in the Immunoglobulin (IgG) replacement therapy market due to its increasing prevalence across the globe. It is the most common type of primary immunodeficiencies which accounts for 50% of cases.
Immunoglobulin (IgG) replacement therapy market is experiencing a rapid boost owing to a growing number of FDA approval. Many companies are entering the market with its innovative products and advanced technology.
Market leaders are focusing on extensive R&D for the development of cost-effective immunoglobulin replacement therapy with lesser side effects. Key players are adopting various strategies such as collaborative agreements, distribution mergers and acquisitions to gain a greater share by increasing market penetration.
Principal Consultant
North America and Europe are expected to dominate the global immunoglobulin (IgG) replacement therapy market due to the increasing awareness of products involved in the treatment of immunodeficiency diseases, developing focus of clinicians towards these therapies.
Increasing healthcare expenditure and awareness in the developing region like Asia-Pacific is expected to drive the global immunoglobulin (IgG) replacement therapy market growth over the forecast period. Rising population in the countries like India and China is further likely to drive the growth of the Immunoglobulin (IgG) replacement therapy market.
Some of the market participants in the global immunoglobulin (IgG) replacement therapy market identified across the value chain include:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Route Of Administration 6.2. Application 6.3. Distribution Channel 7. Global Market Analysis and Forecast, By Route Of Administration 7.1. Intravenous 7.2. Subcutaneous 8. Global Market Analysis and Forecast, By Application 8.1. Hypogammaglobulinemia 8.2. Immunodeficiency Diseases 8.3. Chronic Inflammatory Demyelinating Polyneuropathy 8.4. Congenital AIDS 8.5. Chronic Lymphocytic Leukemia 8.6. Myasthania Gravis 8.7. Multifocal Motor Neuropathy 8.8. Kawasaki Disease 8.9. Others 9. Global Market Analysis and Forecast, By Distribution Channel 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Others 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Asia Pacific 10.5. China 10.6. Japan 10.7. Middle East and Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. China Sales Analysis and Forecast, by Key Segments and Countries 16. Japan Sales Analysis and Forecast, by Key Segments and Countries 17. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Route Of Administration, Application, and Distribution Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Octapharma AG 20.2. Baxter International Inc. 20.3. Grifols 20.4. S.A. 20.5. LFB Group 20.6. CSL Limited 20.7. Kedrion Biopharma 20.8. BDI Pharma Inc. 20.9. Kamada Ltd. 20.10. China Biologics Products, Inc. 20.11. Abeona Therapeutic
Explore Healthcare Insights
View Reports
Immunoglobulin (IgG) Replacement Therapy Market
